Yamada K - Search Results

1

Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer.

Shimokawa T, Yamada K, Tanaka H, Kubota K, Takiguchi Y, Kishi K, Saito H, Hosomi Y, Kato T, Harada D, Otani S, Kasai T, Nakamura Y, Misumi T, Yamanaka T, Okamoto H. Shimokawa T, et al. Among authors: yamada k. Cancer Med. 2021 Jan;10(2):626-633. doi: 10.1002/cam4.3641. Epub 2020 Dec 14. Cancer Med. 2021. PMID: 33319495 Free PMC article. Clinical Trial.

2

Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis.

Yoshida T, Yamada K, Azuma K, Kawahara A, Abe H, Hattori S, Yamashita F, Zaizen Y, Kage M, Hoshino T. Yoshida T, et al. Among authors: yamada k. Med Oncol. 2013 Mar;30(1):349. doi: 10.1007/s12032-012-0349-y. Epub 2012 Dec 22. Med Oncol. 2013. PMID: 23263831

3

Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy.

Yamashita F, Azuma K, Yoshida T, Yamada K, Kawahara A, Hattori S, Takeoka H, Zaizen Y, Kawayama T, Kage M, Hoshino T. Yamashita F, et al. Among authors: yamada k. PLoS One. 2013 Aug 5;8(8):e71356. doi: 10.1371/journal.pone.0071356. Print 2013. PLoS One. 2013. PMID: 23940741 Free PMC article.

4

Feasibility re-evaluation of 75 mg/m² docetaxel in Japanese patients with previously treated non-small cell lung cancer.

Yamada K, Takeoka H, Mizoguchi Y, Yamashita F, Yoshida T, Zaizen Y, Okayama Y, Naito Y, Azuma K, Hoshino T. Yamada K, et al. Jpn J Clin Oncol. 2014 Apr;44(4):338-45. doi: 10.1093/jjco/hyt236. Epub 2014 Jan 30. Jpn J Clin Oncol. 2014. PMID: 24482414

5

Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer.

Takeoka H, Yamada K, Azuma K, Zaizen Y, Yamashita F, Yoshida T, Naito Y, Okayama Y, Miyamoto M, Hoshino T. Takeoka H, et al. Among authors: yamada k. Jpn J Clin Oncol. 2014 May;44(5):472-8. doi: 10.1093/jjco/hyu030. Epub 2014 Mar 30. Jpn J Clin Oncol. 2014. PMID: 24688087 Clinical Trial.

6

Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.

Ishii H, Azuma K, Kawahara A, Yamada K, Imamura Y, Tokito T, Kinoshita T, Kage M, Hoshino T. Ishii H, et al. Among authors: yamada k. J Thorac Oncol. 2015 Mar;10(3):426-30. doi: 10.1097/JTO.0000000000000414. J Thorac Oncol. 2015. PMID: 25384063 Free article.

7

A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911.

Yamada K, Aono H, Hosomi Y, Okamoto H, Kato T, Komase Y, Nishikawa M, Azuma K, Takeoka H, Okuma Y, Nakahara Y, Sato A, Oba MS, Morita S, Kunitoh H, Watanabe K. Yamada K, et al. Eur J Cancer. 2015 Sep;51(14):1904-10. doi: 10.1016/j.ejca.2015.06.120. Epub 2015 Jul 11. Eur J Cancer. 2015. PMID: 26174465 Clinical Trial.

8

Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.

Tokito T, Azuma K, Kawahara A, Ishii H, Yamada K, Matsuo N, Kinoshita T, Mizukami N, Ono H, Kage M, Hoshino T. Tokito T, et al. Among authors: yamada k. Eur J Cancer. 2016 Mar;55:7-14. doi: 10.1016/j.ejca.2015.11.020. Epub 2016 Jan 6. Eur J Cancer. 2016. PMID: 26771872

9

Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802).

Yamada K, Azuma K, Takeshita M, Uchino J, Nishida C, Suetsugu T, Kondo A, Harada T, Eida H, Kishimoto J, Eriguchi G, Takayama K, Nakanishi Y, Sugio K. Yamada K, et al. Anticancer Res. 2016 Jun;36(6):2881-7. Anticancer Res. 2016. PMID: 27272800 Clinical Trial.

10

A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer.

Yamada K, Ichiki M, Takahashi K, Hisamatsu Y, Takeoka H, Azuma K, Shukuya T, Nishikawa K, Tokito T, Ishii H, Hoshino T. Yamada K, et al. Cancer Chemother Pharmacol. 2016 Sep;78(3):501-7. doi: 10.1007/s00280-016-3101-z. Epub 2016 Jul 11. Cancer Chemother Pharmacol. 2016. PMID: 27402398 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11,316 results

Search Page

Filters